Addex Therapeutics Ltd.
corporate_fare Company Profile
Addex Therapeutics Ltd. (NASDAQ:ADXN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ADXN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 8/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for ADXN spans 6-K, 20-F.
Recent high-impact activity:
- Addex Flags Going-Concern Doubt, H1 Loss, and $2.8M ATM Lifeline
- Addex Regains Full Global Rights to GABAB PAM Portfolio from Indivior
- Addex Raises $2.8M via ATM, Extends Cash Runway to Q4 2027
- Shareholders Approve Capital Band Increase, Enabling Future Financing for Distressed Addex Therapeutics
- Addex Therapeutics Reports Increased Q1 Loss, Critically Low Cash, and Going Concern Warning
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 267 shares in ADXN as of the September 15, 2026 settlement, a 93.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 19.4% of ADXN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ADXN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
AGM Convened · Capital Increase Proposal
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ADXN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.